NurExone Biologic Inc. (J90.F)
- Previous Close
0.4080 - Open
0.4150 - Bid 0.4040 x --
- Ask 0.4560 x --
- Day's Range
0.4150 - 0.4150 - 52 Week Range
0.2600 - 0.6000 - Volume
1,000 - Avg. Volume
9,941 - Market Cap (intraday)
33.512M - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. Its technology includes ExoPTEN, for acute spinal cord injury, and glaucoma; and Exosomes, nature's guided missiles for regeneration and healing for specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
nurexone.comRecent News: J90.F
View MorePerformance Overview: J90.F
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: J90.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: J90.F
View MoreValuation Measures
Market Cap
33.92M
Enterprise Value
33.32M
Trailing P/E
--
Forward P/E
6.57
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
20.29
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-135.79%
Return on Equity (ttm)
-517.23%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.04M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
700k
Total Debt/Equity (mrq)
1.87%
Levered Free Cash Flow (ttm)
-2.56M